Skip to main content
Premium Trial:

Request an Annual Quote

Cytovale IntelliSep

Cytovale has launched its IntelliSep prognostic blood test to help emergency departments stratify patients by sepsis risk. The US Food and Drug Administration granted 510(k) marketing clearance for the test in December, and San Francisco-based Cytovale said Our Lady of the Lake Regional Medical Center in Baton Rouge, Louisiana, is the first customer to adopt the test. The IntelliSep test uses high-speed imaging to assess cellular host response through deformability cytometry of leukocyte biophysical properties and returns results in 10 minutes.